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Abstract
Background: Histiocytic sarcoma is a rare disorder in humans, however it is seen with appreciable frequency in
certain breeds of dogs, such as Bernese mountain dog. The purpose of this study was to fully characterize a novel
canine histiocytic sarcoma cell line, and utilize it as a tool to screen for potential therapeutic drugs.
Methods: The histiocytic sarcoma cell line was characterized by expression of cellular markers as determined by
immunohistochemistry and flow cytometry techniques. The neoplastic cells were also evaluated for their capability of
phagocytizing beads particles, and their potential to grow as xenograft in an immunodeficient mouse. We investigated
the in vitro cytotoxic activity of a panel of thirteen compounds using the MTS proliferation assay. Inhibitory effects of
different drugs were compared using one-way ANOVA, and multiple means were compared using Tukey’s test.
Results: Neoplastic cells expressed CD11c, CD14, CD18, CD45, CD172a, CD204, MHC I, and vimentin. Expression of
MHC II was upregulated after exposure to LPS. Furthermore, the established cell line clearly demonstrated phagocytic
activity similar to positive controls of macrophage cell line. The xenograft mouse developed a palpable subcutaneous
soft tissue mass after 29 days of inoculation, which histologically resembled the primary neoplasm. Dasatinib, a tyrosine
kinase pan-inhibitor, significantly inhibited the growth of the cells in vitro within a clinically achievable and tolerable
plasma concentration. The inhibitory response to dasatinib was augmented when combined with doxorubicin.
Conclusions: In the present study we demonstrated that a novel canine histiocytic sarcoma cell line presents a valuable
tool to evaluate novel treatment approaches. The neoplastic cell line favorably responded to dasatinib, which represents a
promising anticancer strategy for the treatment of this malignancy in dogs and similar disorders in humans.
Keywords: Histiocytic sarcoma, Dendritic cell, Cell line, Dog, Small molecule inhibitor
Background
Histiocytic sarcoma (HS) is a highly aggressive hematopoietic
neoplasm in humans and animals. In humans, HS accounts
for less than 1% of all hematopoietic neoplasms [1, 2], affects
all ages, but predominately adults, and involves lymph
nodes and/or a variety of extranodal organs including skin,
bone marrow, spleen, the gastrointestinal tract and the
central nervous system [3, 4]. This malignancy is often
approached with a combination of various modalities
of treatment, including multi-drug chemotherapeutic
protocols, radiation therapy, surgery, and bone mar-
row transplantation [5–7]. However, patients with HS
in general respond poorly to any form of treatment,
therefore this neoplasm carries a poor prognosis and has a
high mortality rate. The low number of clinical cases is a
limitation for an extended understanding of the pathogen-
esis of this disease in people, and restricts the investigation
for novel and more efficacious forms of treatment.
In dogs, a similar disorder is commonly found in certain
breeds, especially the Bernese mountain dog (BMD), in
which the prevalence ranges from 15 to 25% of the popu-
lation [8–12]. The genetic susceptibility to HS in dogs has
been the focus of several investigations. Current published
data of a population of BMD from US and Europe,
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suggests deregulation of the tumor suppressor genes
MTAP/CDKN2A/B located within the region homologous
to human chromosome 9p21 [13, 14]. Studying HS in
dogs is of high importance as, similarly to people, it is a
fatal disease characterized by rapid progression and high
metastatic rate [15–18]. Thus dogs, with spontaneously
occurring HS, are a crucial model for development of new
approaches to treat this orphan disease in people. Affected
canine patients also respond poorly to treatment. The cur-
rently most effective drug is N-(2-chloroethyl)-N′-cyclo-
hexyl-N-nitrosourea (CCNU) that provides a reported
response rate ranging from 29 to 46% for a median sur-
vival time of 85–96 days [16, 19]. A preliminary study
using another cytotoxic drug, doxorubicin, showed a simi-
lar response rate of 46% for a median survival time of
93 days [20]. Additional alternatives of treatment have
been investigated on small cohorts of dogs, including de-
livery of the human MHC non-restricted T-cell line
TALL-104, frameless stereotactic radiosurgery, and
chemotherapy using either paclitaxel or pegylated-
liposomal doxorubicin; however, none has shown promis-
ing results [20–24].
Research groups have demonstrated the therapeutic
potential of drugs as small molecule inhibitors against
HS, based on in vitro studies [25–27]. Screening a large
library of small molecules, Ito et al. successfully identi-
fied eight compounds of high potency (> 60% inhibition)
at concentration of 100 nM [25]. Interestingly, only two
drugs shared the same main target, showing the diversity
of factors driving tumorigenesis in HS, and the potential
benefit of drug combination hitting multiple targets. In
humans, there is only a single report of four patients
with HS treated with small molecule inhibitors, associ-
ated with the overexpression of targets for those drugs
within the neoplasm, however efficacy could not be eval-
uated due to the small cohort of patients [28]. No pub-
lished studies exist reporting the clinical use of small
molecule inhibitors in dogs with HS.
We present here details of a novel HS cell line from a
BMD, named the BD cell line, we have successfully estab-
lished and demonstrated its utility in identification of
potential novel therapeutic options [29]. Considering that
to date, there is no human HS cell line available for
research purposes, we believe that this cell line will provide
an essential scientific tool for the study of this disease.
Methods
Origin of primary tumor
Fresh post-mortem tissue samples from both an abdom-
inal and a pulmonary neoplasm were aseptically ob-
tained from an 8-year-old spayed female BMD presented
to the Michigan State University Veterinary Teaching
Hospital. The diagnosis of HS was based on histopathology
findings of the tumor and positive staining for CD18 by
immunohistochemistry (Fig. 1) [8, 15, 30, 31].
Treatment with various chemotherapeutic agents was
attempted over a year, including CCNU, doxorubicin
and prednisone. The dog responded with only short
periods of tumor remission until the owners opted for
humane euthanasia due to the poor physical condition
of the animal. Samples were collected immediately
following euthanasia under informed owner consent.
Preparation and maintenance of cell culture
The tissue samples were minced in small fragments with
a surgical blade and placed in a solution of Hank’s Bal-
anced Salt Solution with 1% collagenase (Sigma, St.
Louis, MO) for cell disaggregation. After 40 min, the
solution was transferred to a 70 μm cell strainer, and the
filtered portion was plated in Roswell Park Memorial In-
stitute 1640 medium (Life Technologies, Carlsbad, CA)
supplemented with 10% heat-inactivated fetal bovine
serum (FBS) (Life Technologies, Carlsbad, CA), 1%
antibiotic-antimycotic 100X (Life Technologies, Carls-
bad, CA), and 0.1% gentamycin (Life Technologies,
Carlsbad, CA). The cell culture was then incubated at
37 °C in a humidified atmosphere of 5% CO2. For cul-
ture maintenance, the medium was thoroughly changed
every 2–3 days. The cells were confirmed to be of canine
origin and no mammalian interspecies contamination
was detected based on results from CellCheck Plus test
(IDEXX BioResearch, Columbia, MO). A genetic profile
using a panel of microsatellite markers for genotyping is
available and can be used in future monitoring, the
detailed genotype is presented in Additional file 1.
Cytology and immunohistochemistry
Concentrated cytospin slide of cell suspension was
prepared, and stained with Diff-Quik for morphologic
characterization by a board certified veterinary clinical
pathologist. For immunohistochemistry analysis of the
cell line, the cell pellet was fixed in 10% formalin for
up to 24 h and transferred to 70% ethanol until
embedding in paraffin. Sections from the paraffin
block containing the cell pellet were deparaffinized in
xylene and rehydrated in ethanol at different concentra-
tions. Hydrogen peroxide 3% was used to neutralize
endogenous peroxidases.
Antigen retrieval of formalin-fixed, paraffin embedded
tissues was performed on the PT Link (Dako North
America), using the EnVision FLEX Target Retrieval So-
lution, Low pH (Dako North America) for 20 min. For
immunolabeling with the primary antibodies (CD3,
CD18, CD79a and CD204), sections were processed with
the Autostainer Link 48 (Dako North America, Carpin-
teria, CA) using the EnVision Flex+ detection system
(Dako North America), and the immunoreaction was
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visualized with 3,3′-diaminobenzidine substrate (DAB)
(Dako North America) and sections were counterstained
with haematoxylin. For immunolabeling with antibody
vimentin, the Discovery Ultra Automated Staining system
(Ventana Medical Systems, Inc., Tucson, Arizona) was
used with UltraMap alkaline phosphatase red detection
system (Ventana Medical Systems, Inc) with a red
chromogen. Antigen retrieval was achieved using the Ven-
tana medical System antigen retrieval solution CC1 (Ven-
tana Medical Systems, Inc., Tucson, Arizona) for 60 mins.
Details of the antibodies are available in Additional file 2.
Flow cytometry
BD cells harvested from cell culture were labeled with
the following monoclonal antibodies: anti-canine CD3
(CA17.2A12, Serotec), anti-canine CD11c (CA11.6A1,
UC Davis/NIH NeuroMab Facility), anti-bovine CD14
(MM61A, WSU MAC), anti-canine CD21 (CA2.1D6,
Serotec), anti-canine CD45 (YKIX716.13, Serotec), anti-
canine CD79a (HM57, LS Bio), anti-bovine CD172a
(DH59B, WSU MAC), anti-canine MHC II (YKIX334.2,
eBioscience), and anti-bovine MHC I (MHC CL I, WSU
MAC). Isotype matched control antibodies were used to
exclude non specific binding. The flow cytometers BD
LSR II and BD Accuri C6 (BD Bioscience, Bedford, MA)
were used for analysis. For the stimulation studies, BD
cells were treated with either LPS 50 ng/ml (Sigma Al-
drich, St. Louis, MO) or IFNγ 50 ng/ml (Peprotech,
Rocky Hill, NJ), for 24 and 48 h. Details of antibodies
are listed in Additional file 2.
Phagocytosis assay
The phagocytic and endocytic properties of the estab-
lished cell line were evaluated using 2% pHrodo™ E. coli
Bioparticles® (Life Technologies, Carlsbad, CA). Using a
24-well plate, 100,000 cells were plated per well and left
overnight. Culture medium was removed and replaced
by 2% pHrodo™ E. coli Bioparticles® diluted in Live Cell
Imaging Solution (Life Technologies, Carlsbad, CA) for
1.5–2 h before imaging. Confocal images were obtained
using Leica TCS SPE confocal system (Leica Microsys-
tems, Buffalo Grove, IL) on excitation wavelength of
460 nm. Commercially available murine macrophage cell
line J774.A (ATCC® TIB-67™), a canine HS cell line
DH82, derived from a macrophage derived sarcoma,
hemophagocytic HS (ATCC® CRL-10389™), and canine
fibroblasts isolated from the tunica albuginea were used
for functional comparison purposes.
Neoplastic cell growth and characterization in a xenograft
mouse
In order to evaluate the ability of the cells to form tumor
in vivo, 1 × 106 neoplastic cells were injected into one
ten-week old female mouse of NOD scid gamma strain
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson Labora-
tory, Bar Harbor, ME). One million cells were suspended
in 100 μl of Dulbecco’s Modified Eagle Medium (Life
Fig. 1 Histopathology and immunohistochemistry analysis of the primary neoplastic tissue. Sections of lung stained with hematoxylin and eosin
(H&E) with a well-demarcated region of neoplastic cells replacing the normal pulmonary parenchyma. Neoplastic cells presented as a
highly pleomorphic population of malignant histiocytic cells with marked anisocytosis and anisokaryosis. The cells contained large
amounts of basophilic and typically mildly vacuolated cytoplasm. Multinucleation, megalocytosis and megalokaryosis were common
features. One to several prominent nucleoli were present in most nuclei. Perimembranous expression of CD18 was strongly detected
by immunohistochemistry
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Technologies, Carlsbad, CA) with 10% FBS, and mixed
with BD Matrigel™ Matrix HC in 1:1 ratio (BD Biosci-
ences, San Jose, CA). The cell suspension was then inoc-
ulated subcutaneously into the left flank of the mouse
under anesthesia.
The tumor growth in the inoculated mouse was
monitored daily using calipers, until the tumor mea-
sured close to 10 mm in diameter as this was one of
our humane endpoints. The mouse was sacrificed
using carbon dioxide gas, and a full necropsy evalu-
ated the presence of metastases into other organs.
Tissues that had macroscopic changes were fixed in
10% formalin, routinely processed, and embedded in
paraffin wax. Paraffin sections were stained with H&E for
microscopic examination. For further characterization of
the neoplasm, immunohistochemistry for CD18 was per-
formed on paraffin sections.
Drug-screening assays
For the drug-screening assays, we used both the BD cell
line, and the DH82 (CRL-10389™ - ATCC®) cell line, estab-
lished from a golden retriever with hemophagocytic HS. In
total, 13 drugs (Table 1) were tested from stock solutions
prepared with the appropriate solvent as indicated, stored
at − 20 °C, and protected from light. Serial dilutions of
each drug were made from the stock solutions in culture
medium immediately before adding to the cells in such a
way that the solvent concentration was always < 1%. Each
compound was tested at different concentrations in order
to bracket the corresponding IC50 (concentration of drug
necessary to inhibit the cell growth by 50%).
Viability assay and data analysis
For viability assay, DH82 and BD cell lines were seeded
on 96-well plates with 7500 cells/well and 12,000 cells/
well, respectively. After a 24-h incubation time, the
cell culture medium was replaced with 100 μl of
complete medium with drug, and cells were then
incubated for 72 h. Subsequently, the viability of the
cells was analyzed using a CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS) (Promega,
Madison, WI). The formazan product was measured using
EnVision® Multimode Plate Reader (PerkinElmer, Wal-
tham, MA) at a wavelength of 490 nm. Each experiment
was run in triplicate.
The background absorbance was subtracted from the
absorbance values generated by the cells exposed to
drugs. The effect on cell viability caused by each drug
was calculated as follows: viability (%) = [1-(A-B)/(C-B)]
× 100, where A is the response with drug, B is the back-
ground response with no drug, and C is the response
with vehicle. The absorbance generated by the “cells
alone” control was denoted as AbsIC100 (100%) and the
absorbance generated by water control was denoted as
AbsIC0 (0%). The calculated percentage at each (log10)
drug concentration was then plotted using GraphPad
Prism 5 software nonlinear regression curve fitting
(PRISM 5, GraphPad Software, La Jolla, CA). The IC50
was determined as the drug concentration correspond-
ing to the value of the mean between 0 and 100% viabil-
ity. “Cells alone” control was treated with the vehicle
DMSO 1%, the same concentration used to the cells ex-
posed to the drugs.
Drug combination assays
Both HS cell lines were counted and seeded in 96-well
plates as described in Viability assay and data analysis
section. Each cell line was incubated with 5 different
concentrations of dasatinib with or without doxorubicin.
The concentrations of dasatinib were defined to bracket
Table 1 List of drugs from drug-screening assay with their respective solvent, and main known targets
Name Solvent Main Targets [65–71]
Dasatinib DMSO ABL, PDGFR, KIT, SRC
Erlotinib DMSO EGFR
Gefitinib DMSO EGFR
Imatinib DMSO ABL, PDGFR, KIT
Masitinib DMSO c-KIT, PDGFRα, −β, Lyn, FGFR3, FAK pathway
Nilotinib DMSO ABL, PDGFR, KIT
Toceranib DMSO VEGFR2, PDGFRβ, c-KIT
Sorafenib DMSO VEGFR2, PDGFR, KIT, FLT3, BRAF
Sunitinib DMSO VEGFR, KIT, PDGFR, RET, CSF1R, FLT3
Tozasertib DMSO SRC, GSK3, FLT3, JAK2, BCR-ABL
CCNU Ethanol Alkylation and cross-linking of DNA
Cladribine DMSO Purine analogue
Doxorubicin Saline Inhibits DNA topoisomerase II, induces DNA damage and apoptosis
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the IC50 for each cell line, and the concentration of dox-
orucibin was fixed with the concentration necessary to
inhibit cell viability by 70%. Cell viability was measured
by MTS proliferation assay after 72 h of incubation.
Each experiment was run in triplicate.
Western blotting
BD cells were treated with either vehicle (0.1%) or dasa-
tinib for 4 h. Cells were lysed using CellLytic M (Sigma-
Aldrich) supplemented with 1% protease inhibitor and
phosphatase cocktail inhibitor (P8340/P5726 – Sigma-
Aldrich). A total of 40 μg of protein per lane were sepa-
rated by Novex NuPAGE SDS-PAGE (4–12%), and
transferred to polyvinylidene difluoride membrane.
Membranes were blocked with 5% BSA in TBS buffer,
and probed overnight with monoclonal rabbit anti-
human antibodies against phospho-SRC (44-660G,
Thermo Fisher) or SRC (2109, Cell Signaling), and
monoclonal mouse anti-human β-actin (8H10D10, Cell
Signaling). Secondary antibodies include IRDye 800CW
goat anti-mouse and 680RD goat anti-rabbit (LI-COR).
Infrared fluorescence was detected using Odyssey Im-
aging System (LI-COR), and analyzed using Image Stu-
dio™ Lite software (LI-COR).
Statistical analysis
Comparison of means of the cell viability rate among
groups of different drug concentrations was done by one-
way ANOVA, followed by Tukey’s multiple means com-
parison test. In order to determine whether the addition
of dasatinib to doxorubicin increased the anti-proliferative
effect, two-way ANOVA was utilized. Statistical analyses
were performed using GraphPad Prism 5 software (PRISM
5, GraphPad Software, La Jolla, CA). Differences were
considered statistically significant when p < 0.05.
Results
Characteristics of BD cell line
Neoplastic cells in culture grew satisfactorily in 10% FBS
without the addition of specific growth factors with the
vast majority of the population growing as adherent and
non-clustering cells. BD cell line was maintained in
tissue culture for a minimum of 50 passages over
12 months, with a doubling time of approximately 36 h.
Cytospins stained with Diff-Quik from cells harvested
from cell culture showed the presence of significant
cellular pleomorphism, marked anisocytosis and aniso-
karyosis. Giant cells and multinucleation were frequently
observed (Fig. 2).
The established cell line showed lack of expression of
both CD3 and CD79a, and positive expression of CD18,
CD204 and vimentin on immunohistochemistry, consist-
ent with features observed initially in the primary neo-
plasm (Fig. 3). The positive expression of myeloid
marker CD45 and the lack of expression of lymphoid
markers CD3, CD21 and CD79a were confirmed by flow
cytometry. BD cell line expressed CD11c, CD14,
CD172a and MHC I at a high level, and MHC II at a
lower level (Fig. 4). MHC II expression was not affected
by the stimulation with IFNγ, however it was significantly
increased under the stimulation with LPS over time.
Phagocytic properties of BD cell line
For the phagocytosis assays, the majority of cells from
BD cell line were capable of phagocytizing the bioparticles,
demonstrated by fluorescent intracellular signal on most
of the cells (Fig. 5a). Both the murine macrophage cell line
J774A.1 and the canine HS cell line DH82 demonstrated a
high capability of phagocytosis, as expected (Fig. 5b and c).
In contrast, we observed the presence of the bioparticles
inside only a few canine fibroblasts (Fig. 5d).
Experiment with xenograft mouse
The xenograft mouse developed a palpable soft tissue
mass of 5 mm of diameter detected at the injection site
29 days after injection. The tumor increased rapidly in
size over 6 days until it reached 10 mm of diameter,
when the mouse was humanely euthanized. A full nec-
ropsy revealed a large lobulated subcutaneous mass at
the injection site measuring 25 × 15 × 10 mm, showed in
more detail in Additional file 3. The neoplasm had
locally invaded the musculature of the abdominal wall
dorsally to the tumor. No other significant macroscopic
changes were observed in other organs.
Evaluation of inhibitory effects of drugs on the growth of
canine HS cells
The inhibition of cell growth by the drugs was variable
between the two HS cell lines, BD and DH82. Dose-
Fig. 2 Image of BD cell cytospin stained with Diff-Quik showing a
population of pleomorphic neoplastic round cells with marked ani-
socytosis and anisokaryosis with numerous binucleated and multinu-
cleated cells. Calibration bar: 50 μm
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response curves were generated based on the cell viabil-
ity at various concentrations of drug, from which IC50
values were determined. The results of IC50 (Table 2)
values indicated that across 13 drugs tested, only dasati-
nib and doxorubicin were capable of inhibiting the
growth of HS cells, within a pharmacologically relevant
concentration. Both drugs exhibited statistically signifi-
cant inhibitory effects on cell growth in a dose
dependent manner using one-way ANOVA analysis (p <
0.0001). The IC50s of dasatinib were 10 and 9 nM, and
of doxorubicin were 90 and 412 nM for BD and DH82
cell lines, respectively (Fig. 6). These concentrations
were within the known tolerable plasma concentration
values (Table 2). The maximum achievable plasma
concentrations of the drugs were based on the plasma
concentration values of the no-observed-adverse-effect
level (NOAEL), or on the level of the therapeutic dosage
described in the veterinary and human medicine litera-
ture. When available, the plasma concentration values
encountered for dogs were used over those for humans.
Results of IC50 (nM) values of drugs for each HS cell
line, and associated values of achievable plasma concen-
tration described in the veterinary and human medicine
literature.
Exploring synergistic combinations of drugs
We next assessed the resulting cytostatic effect caused by
increasing concentrations of dasatinib combined to doxo-
rubicin at a fixed concentration close to the correspondent
cell line’s IC50. When BD cell line was treated with the
drug combination for 72 h, there was no significant in-
crease in the antiproliferative activity in comparison to the
cells treated with dasatinib alone. On the other hand,
dasatinib and doxorubicin combination significantly in-
creased the inhibitory effect on the growth of DH82 cells
(p = 0.0003) (Fig. 7).
Effect of dasatinib on SRC activity
The expression of total SRC and phopho-SRC was evalu-
ated on cells treated with escalating concentrations of
Fig. 3 Immunohistochemistry of BD cell line showing strong expression of CD18, vimentin, and CD204, while being negative for CD3 and
CD79a expression (left column). Middle and right columns are negatitve control and positive control sections, respectively. For CD18, CD204, CD3
and CD79a antibodies, DAB chromogen was used; and for vimentin antibody, alkaline phosphatase red chromogen. Calibration bar: 50 μm
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dasatinib. We observed a decrease in phospho-SRC but
not in total SRC in both cell lines, BD and DH82, after 4 h
of treatment. Expression of phosphor-SRC was minimal at
the concentration of 100 nM of dasatinib (Fig. 8).
Discussion
The use of the naturally occurring histiocytic sarcoma in
the dog as a translational model for human HS repre-
sents a valuable opportunity to further understand this
Fig. 4 Flow cytometry results for expression of CD45, CD3, CD21, CD79a, CD14, CD172a, CD11c, MHC I, and MHC II. Expression of MHC II was also
evaluated on cells treated with either LPS or IFNγ for 24 and 48 h. (BD cell line shown in red, isotype control in blue)
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malignancy, and to find better tools for treatment. In
this article we have presented the initial characterization
of a novel HS cell line - BD cell line - and investigated
potential novel treatment approaches.
Histiocytic sarcomas are frequently associated with a
high level of cellular pleomorphism, therefore, the
definitive diagnosis is determined by a pattern of expres-
sion of markers specific for histiocytes. Although, several
markers have been used to characterize human HS includ-
ing CD163, CD68, CD11c, lysozyme, and CD14 [4, 32, 33],
two different markers were validated for HS tumors in
dogs: CD18 (integrin beta chain beta 2) and CD204 (class
A macrophage scavenger receptor) [8, 15, 30, 31, 34]. The
novel BD cell line showed positive expression of CD18
and CD204, consistent with the diagnosis of HS. The
negative expression of CD3, CD21 and CD79a excluded
lymphoid malignancies, while positive vimentin, a type III
intermediate filament protein, confirmed the mesenchy-
mal origin, and positive CD45 confirmed the myeloid ori-
gin. Interestingly, the stimulation of BD cells with LPS, a
Fig. 5 PHrodo Phagocytosis assay with strong uptake of red particles by the (a) BD cell line, the (b) canine HS cell line DH82, the (c) murine
macrophage cell line J774A.1, and weak uptake by (d) canine fibroblasts
Table 2 Results from drug screening and referenced achievable plasma concentrations
Drug IC50 (μM) Achievable concentrations in plasma (based on the literature)
BD DH82 [plasma] (μM) Species Dose Effect Ref.
Dasatinib 0.01 0.009 0.3 dog 3 mg/kg NOAEL [72]
Erlotinib 3.2 4.3 6.9 dog 150 mg TD [73]
Gefitinib 30.7 46.4 2.6 dog 100 mg/kg NOAEL [74]
Imatinib 34 39.2 0.66 dog 10 mg/kg NOAEL [75]
Masitinib 15.7 39.1 1.5 dog 10 mg/kg TD [76]
Nilotinib 29.9 26.2 1.4 dog 20 mg/kg NOAEL [77]
Toceranib 1.9 1.7 0.1 dog 3.25 mg/kg TD [78]
Sorafenib 36.3 13.6 13.3 human 400 mg TD [79]
Sunitinib 4.5 17.9 0.12 human 50 mg TD [80]
Tozasertib 7.7 1.3 0.27 human 8 mg/m2 TD [81]
CCNU 105 139.5 4.2 human 130 mg/m2 TD [69]
Cladribine a 64 222 0.028 human 0.09 mg/kg TD [82]
Doxorubicin a 0.09 0.41 1.13 dog 30 mg/m2 TD [83]
a Compounds administered intravenously
NOAEL: no-observed-adverse-effect level
TD: therapeutic dosage
Takada et al. BMC Cancer  (2018) 18:237 Page 8 of 13
lipopolysaccharide component of Gram-negative bacteria
walls, resulted in increased expression of MHC class II. A
similar increase in MHC Class II expression was reported
when murine dendritic cells were exposed to LPS, includ-
ing CD14 positive dendritic cells [35, 36]. CD14 expression
is mainly present in macrophages and monocytes, however
it can also be found in DCs, where it has been proposed to
play a role on the immunologic responses in DCs [37].
The same effect was not observed when the cells were
stimulated with interferon-γ (IFNγ). Due to the fact that
the majority of BD cells expressed MHC I and MHC II,
we could confirm an antigen presenting cell profile. Both
macrophages and DCs are antigen presenting cells that,
despite their differences in biological functions, are only
distinguished by a few surface markers. Candidate markers
that have an increased specificity for DC and DC subsets
have been identified in several studies [38–41]. Two DC-
specific markers were tested in the present study, CD11c
and CD172a, for which the vast majority of BD cells were
positive. Together, these findings indicated a pattern of
expression associated with a dendritic cell origin.
Dendritic cells are professional phagocytes that have
an important role in processing antigens for adaptive
immune recognition [42]. The majority of cells from the
newly established cell line were able to phagocytize
pHrodo E. coli bioparticles when coincubated for 2 h. In
this assay, the bioparticles would only emit fluorescence
once they are inside the phagosomes of the cells, where
the pH is low. Therefore, this pH-sensitive fluorescent
method permits a clear discrimination of where the par-
ticles are located in respect to the cells [43]. As a repre-
sentation of positive controls for this assay, the two
macrophage cell lines, J774.A and DH82, showed a high
level of phagocytosis. In contrast, we could appreciate
phagocytic activity in only a very small number of canine
fibroblasts, which were used as negative control.
When transplanted to an immunodeficient xenograft
mouse, BD cell line successfully grew as a palpable soft
tissue mass after 29 days, a time-frame comparable to
other tumor xenograft studies [44]. We were able to
confirm that BD cell line is a tumorigenic cell line,
and could potentially be useful for in vivo studies as
an experimental tool to study histiocytic sarcoma.
Further studies with a larger number of animals are
warranted to truly establish the transplantability and
metastatic potential. A few xenograft mouse models
of canine HS have been successfully established and
were used for the evaluation of their metastatic po-
tential, and to study the phenomenon of resistance to
CCNU-based treatment [45, 46]; however, none of
these cell lines had originated from BMDs, the most
frequently affected breed. To the best of our know-
ledge, across the many existent canine HS cell lines,
only two others were reported to be originated from
tumors of BMDs [47]; and these two were not part of
their drug response report.
Fig. 6 Dose-dependent antiproliferative activity of doxorubicin (a) and dasatinib (b) against BD and DH82 cells after 72 h of treatment. Cells
treated with vehicle DMSO were used as control cells
Fig. 7 The effect of dasatinib on cell viability administered alone and in combination with doxorubicin on BD (a) and DH82 (b) cell lines
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Results from the in vitro drug screening experiment
showed a variable response between the different drugs,
and across the cell lines. Across a total of 13 com-
pounds, dasatinib and doxorubicin effectively inhibited
the cell growth of both HS cell lines within a clinically
tolerable and achievable plasma concentration according
to the veterinary and human literature.
Doxorubicin was the only conventional chemothera-
peutic drug that elicited a favorable response against the
HS cell lines. Several studies have reported the use of
doxorubicin for the treatment of histiocytic disorders,
including HS [5, 6, 33, 48–51]. Due to the low number
of cases, the effectiveness of doxorubicin could not be
determined in those studies, especially as single agent, as
the drug was invariably used in a drug combination
protocol. Our results agree with previous in vitro studies
that considered doxorubicin an effective drug against
canine HS [20, 52]. The potential of doxorubicin for the
treatment of dogs with HS was suggested by a prelimin-
ary clinical study, where the response to doxorubicin
was comparable to the response to the drug with the
best response reported to date, CCNU [20].
Our positive results with dasatinib are in accordance
with results from a study by Ito et al., where dasatinib
was effective against 4 out of 7 canine HS cell lines de-
rived from various breeds. The calculated IC50 values
from that study varied from 5.4 to 54.5 nM, while the
average IC50 value in our study was 9.5 nM, clearly
within their range [25]. Dasatinib is an multi tyrosine
kinase inhibitor with multiple main targets, including
the SRC family kinases (SRC, LCK, YES, and FYN), the
BCR-ABL, and to a lesser extent, c-KIT, PDGFRβ and
EPHA2 [53]. We demonstrated that dasatinib inhibited
the activation of SRC, as revealed by decrease of p-SRC
(phospho-SRC) in both cell lines, BD and DH82. We
hypothesize that the downregulation of p-SRC could be
associated with the inhibitory effect of dasatinib on the
HS cell lines, however, as a multi-kinase inhibitor, many
other molecular targets might also be affected. However,
the SRC pathway is a major oncogenic driver involved in
HS against which dasatinib and other novel compounds
may be used. Although dasatinib has been investigated
in many human cancers, its clinical therapeutic value
for HS has never been documented. [54–58]. How-
ever, the use of other small inhibitors for the
treatment of HS has been reported in one study
where human patients were treated with imatinib,
sorafenib and bevacizumab, based on the pattern of
expression of key molecular targets [28]. Another set
of studies reported two patients carrying a HS asso-
ciated with a mutation in BRAFV600E gene, most
commonly seen in melanomas in humans [50, 59].
Neoplasms that are driven by this mutation are suit-
able for vemurafenib-based treatment, a B-Raf small
molecule inhibitor. In fact, a human patient from
one of the studies was treated with vemurafenib and
experienced therapeutic response for a couple of
months [59]. Although the efficacy of these drugs
could not be evaluated due to the small cohort of
patients, the identification of druggable targets in HS
shows the value of targeted therapy for this disease.
We demonstrated that the combination of dasatinib
and doxorubicin resulted in a favorable additive effect
against one of the two HS cell lines, DH82 cell line.
The association of small inhibitors with chemothera-
peutic drugs has been strategized as a treatment with
broader spectrum, which resulted in synergistic anti-
cancer activity for many tumors [26, 60, 61]. Often
the increased efficiency is accompanied with a dose
reduction of the drugs, and consequently decreased
treatment related side effects. The combination of
drugs with different mechanisms of action should be
considered as a relevant strategy to optimize the
therapeutic effect of each inhibitor against HS.
Conclusions
The present study was able to establish and fully
characterize a DC-subtype HS cell line from a tumor
in a BMD. This novel HS cell line represents a model
available not only for the investigation of potential
therapeutic drugs, but also for the studies of gene ex-
pression and genetic variability associated with HS.
The existence of cancer cell lines has been a critical
tool for the understanding of cancer biology and re-
sponse to therapy. For that matter, panels of human
cancer cell lines such as NCI60 and GDSC have be-
come available for researches, so that the collective
use of these resources would generate more effi-
ciently information including genomics and drug
sensitivity of these cell lines [62, 63]. Nevertheless, it
is valuable to mention that cell lines are prone to
genetic changes over time, and early passages should
be a better model of the tumor of origin. More
recently, a panel of canine cancer cell lines has been
created covering the most important cancers seen in ca-
nine patients [64]. Due to the rarity of HS in humans,
studies based on spontaneous HS in dogs can provide im-
portant and relevant translational understanding of this
malignancy. Moreover, we also propose BD cell line as a
Fig. 8 The effect of dasatinib on expression of phospho-SRC on BD
and DH82 cell lines
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useful system for studies where a cell line of dendritic cell
origin can be of value.
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Additional file 3: Xenograft tumor in a mouse. On necropsy, a large
lobulated subcutaneous mass was present at the site of injection of
tumor cells 35 days after transplantation (black arrow). (TIFF 7833 kb)
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